

**Summary statistics - quantitative results**

Deadline: 7.4.2023

**EQA round: KD2/23 - Glycated Haemoglobin**  
Setup: groups - manufacturer of kit; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D <sub>max</sub> = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N <sub>tot</sub> = total number of the results		N <sub>eva</sub> = number of the results assessed
N <sub>out</sub> = number of the results removed before calculation		N <sub>suc</sub> = number of successful results
		S <sub>rel</sub> = relative success

Test <b>Sample</b> Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability							N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL					
(220) <b>Haemoglobin A<sub>1c</sub></b>	[mmol/mol]				139									139	138	99
<b>Sample A</b>		58,5	2,5	4,3	139		CVP	58,5	0,53	12%	51,4	65,6		139	139	100
(14) Bio-Rad		59,4	2,1	3,5	43	0										43
(25) TOSOH		58,8	1,7	2,9	42	0										42
(60) Roche		60,7	2,5	4	7	0										7
(150) Arkray		56	1,6	2,9	37	0										37
Other					10	0										10
							1x 1, 2x 34, 3x 46, 2x 58, 1x 177, 1x 999									
<b>Sample B</b>		41,7	2	4,8	139		CVP	41,7	0,41	12%	36,6	46,8		139	138	99
(14) Bio-Rad		42,3	2	4,8	43	0										43
(25) TOSOH		42	1,5	3,7	42	0										42
(60) Roche		43	1,3	2,9	7	0										7
(150) Arkray		40	1,4	3,6	37	0										37
Other					10	0										10
							1x 1, 2x 34, 3x 46, 2x 58, 1x 177, 1x 999									